Oct 1, 2014
|
Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients
|
Sep 5, 2014
|
Ardelyx Chief Scientific Officer, Dominique Charmot, Announces Retirement from the Company at Year-End
|
Aug 7, 2014
|
Ardelyx Reports Second Quarter 2014 Financial Results
|
Aug 5, 2014
|
Ardelyx to Present at the Wedbush 2014 Life Sciences Management Access Conference
|
Jun 24, 2014
|
Ardelyx Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
|
Jun 18, 2014
|
Ardelyx Announces Pricing of its Initial Public Offering
|
May 15, 2014
|
Ardelyx Receives $25 Million Milestone From AstraZeneca For Commencement Of Phase 2b Clinical Trial Of Tenapanor
|
Feb 24, 2014
|
Ardelyx Licenses NaP2b Phosphate Inhibitor Program for Kidney Disease to Sanofi in Deal Worth Up to $198 Million.
|
Jan 13, 2014
|
Ardelyx Receives $15 Million Milestone as Part of Ongoing Tenapanor Collaboration with AstraZeneca
|
Oct 8, 2012
|
AstraZeneca and Ardelyx Announce Worldwide Licensing Deal For NHE3 Inhibitor Programme For Complications Of Renal Disease, Including Diabetes-Induced Renal Disease.
|